News
Sixth Annual Neuroscience and Yoga Conference Announced by NeuroYogaNYC
1+ hour, 37+ min ago (250+ words) Join us online - accessible regardless of your time zone or schedule The conference will delve into three pivotal topics: Yoga + Migraine and Headache, Yoga + Schools and Neurodiversity, and Yoga + Brain Longevity. These sessions aim to equip participants with evidence-based knowledge…...
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
1+ day, 5+ hour ago (322+ words) Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory…...
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in...
1+ day, 20+ hour ago (575+ words) U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in... - Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in…...
Blue-Light-Blocking Glasses For Better Sleep: Quality Night-Time Range Update
2+ day, 4+ hour ago (346+ words) Sleep ZM announces updates to its blue-light-blocking glasses for nighttime use, featuring precision-engineered frames and lenses designed to filter blue light wavelengths that research shows can disrupt natural sleep patterns. Gainesville, United States, February 20, 2026 -- As screen time continues to increase…...
Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting
2+ day, 4+ hour ago (92+ words) Poster presentation details are as follows: Poster Number: 610Poster Session: Anaphylaxis and Venom AllergyPresentation Time: Sunday March 1st, 9:45 am - 10:45 amLead Author: Matthew Greenhawt, MD, MBA, MSc Poster Title: Novel Sublingual Epinephrine Is Not Associated with a Diastolic Blood Pressure Dip Poster Number:…...
ABLi Therapeutics Announces Publication of the Final Results from the Phase 2 ‘201 Trial’ Evaluating Risvodetinib for the Treatment of Parkinson’s Disease
2+ day, 16+ hour ago (697+ words) ABLi Therapeutics (ABLi), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine Kinases (c-Abl kinases), announces publication of the ... ABLi Therapeutics Announces Publication of the Final Results from the Phase 2 "201 Trial" Evaluating Risvodetinib for…...
CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference
2+ day, 16+ hour ago (358+ words) CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference Leronlimab-mediated CCR5 blockade…...
Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers
2+ day, 18+ hour ago (548+ words) " Administration of PEDMARK" Approximately Six Hours After Cisplatin was Shown to Be Safe & Easily Integrated into Care for Adults with Head & Neck Cancers (HNC) " " Early Signals of Hearing Preservation Highlight the Potential of PEDMARK" to Address Cisplatin-Induced Hearing Loss, a…...
Curaechoice and The Center for Pain to Deliver No-Cost Pain Management to Members Nationwide
2+ day, 18+ hour ago (178+ words) Birmingham, ALABAMA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Curaechoice, the nation's #1 leader in No-Cost Benefits Optimization, announced a new nationwide partnership with The Center for Pain, one of the nation's leading interventional pain management providers dedicated to relieving pain, restoring function, and improving…...
Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina
2+ day, 19+ hour ago (259+ words) Collaboration with Intec SRL drives commercial expansion of 3D medical imaging across a high-growth private healthcare market PETACH TIKVA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (Nanox, Nasdaq: NNOX), a leader in innovative medical imaging technology, today announced a distribution agreement…...